Skip to content
Life Sciences Series A Founded 2019

LAPIX

Developer of immunotherapies for immunological diseases

📍 Boston, United States · Immunology

Funding snapshot

Last roundSeries A
Amount$2M
Date21 July 2025

About

Developer of immunotherapies for immunological diseases. It offers a lead candidate LPX-TI641 for multiple sclerosis, Neuromyelitis Optica, Rheumatology, LPX-TIIBD for Inflammatory bowel disease, and also provides gene therapy.

Latest news

No articles yet.

Raising like LAPIX?

Analyze your pitch deck before your next raise.

Analyze My Deck →